Arcellx
ACLX
Market cap $5.12B

95.27 USD

+2.27

2.44%

At close Oct 17, 4:00 PM EDT

After hours

95.27

+0.00

0.00%

1 day

2.44%

5 days

15.24%

1 month

22.16%

3 months

45.43%

6 months

77.91%

Year to date

69.67%

1 year

170.96%

5 years

467.08%

About: Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Employees: 130

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

72% more call options, than puts

Call options by funds: $5.29M | Put options by funds: $3.07M

58% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 50

33% more funds holding in top 10

Funds holding in top 10: 9 [Q1] → 12 (+3) [Q2]

3.37% more ownership

Funds ownership: 90.51% [Q1] → 93.88% (+3.37%) [Q2]

8% less funds holding

Funds holding: 180 [Q1] → 166 (-14) [Q2]

17% less capital invested

Capital invested by funds: $3.32B [Q1] → $2.77B (-$551M) [Q2]

39% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 36

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$81

15%

downside

Avg. target

$94

2%

downside

High target

$115

21%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity John Newman 45% 1-year accuracy 10 / 22 met price target	21%upside $115	Buy Maintained	17 Oct 2024
Needham Gil Blum 38% 1-year accuracy 52 / 137 met price target	15%downside $81	Buy Reiterated	9 Aug 2024
Canaccord Genuity John Newman 45% 1-year accuracy 10 / 22 met price target	11%downside $85	Buy Maintained	22 Jul 2024

See Analyst Rankings

Financial journalist opinion

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million.

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Zacks Investment Research

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago.

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2024. “We continue to make significant strides as we accelerate our business,” said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. “We are thrilled about the m.

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results. Anito-cel has demonstrated a 100% overall response rate and a 76% complete response rate in early trials. The collaboration with Kite enhances Arcellx's operational capabilities and financial stability, supporting the development of Anito-cel.

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

7 Biotech Stocks to Put on Your Breakthrough Radar

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.

7 Biotech Stocks to Put on Your Breakthrough Radar

Zacks Investment Research

Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.58 per share a year ago.

Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Arcellx Provides First Quarter 2024 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Cash, cash equivalents, and marketable securities: As of March 31, 2024, Arcellx had cash, cash equivalents, and marketable securit.

Arcellx Provides First Quarter 2024 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™